JSI 1187
Alternative Names: JSI-1187Latest Information Update: 17 Jul 2024
At a glance
- Originator JS InnoPharm (Shanghai)
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 02 Feb 2024 JSI 1187 is still in phase I trials for Solid tumors in USA (NCT04418167)
- 28 Sep 2023 JS InnoPharm suspends phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) due to sponsor decision (NCT04418167)